1
|
Lee MK, Basch E, Mitchell SA, Minasian LM, Langlais BT, Thanarajasingam G, Ginos BF, Rogak LJ, Mendoza TR, Bennett AV, Schrag D, Mazza GL, Dueck AC. Reliability and validity of PRO-CTCAE® daily reporting with a 24-hour recall period. Qual Life Res 2023; 32:2047-2058. [PMID: 36897529 PMCID: PMC10241696 DOI: 10.1007/s11136-023-03374-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/10/2023] [Indexed: 03/11/2023]
Abstract
PURPOSE The standard recall period for the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) is the past 7 days, but there are contexts where a 24-hour recall may be desirable. The purpose of this analysis was to investigate the reliability and validity of a subset of PRO-CTCAE items captured using a 24-hour recall. METHODS 27 PRO-CTCAE items representing 14 symptomatic adverse events (AEs) were collected using both a 24-hour recall (24 h) and the standard 7 day recall (7d) in a sample of patients receiving active cancer treatment (n = 113). Using data captured with a PRO-CTCAE-24h on days 6 and 7, and 20 and 21, we computed intra-class correlation coefficients (ICC); an ICC ≥ 0.70 was interpreted as demonstrating high test-retest reliability. Correlations between PRO-CTCAE-24h items on day 7 and conceptually relevant EORTC QLQ-C30 domains were examined. In responsiveness analysis, patients were deemed changed if they had a one-point or greater change in the corresponding PRO-CTCAE-7d item (from week 0 to week 1). RESULTS PRO-CTCAE-24h captured on two consecutive days demonstrated that 21 of 27 items (78%) had ICCs ≥ 0.70 (day 6/7 median ICC 0.76), (day 20/21 median ICC 0.84). Median correlation between attributes within a common AE was 0.75, and the median correlation between conceptually relevant EORTC QLQ-C30 domains and PRO-CTCAE-24 h items captured on day 7 was 0.44. In the analysis of responsiveness to change, the median standardized response mean (SRM) for patients with improvement was - 0.52 and that for patients with worsening was 0.71. CONCLUSION A 24-hour recall period for PRO-CTCAE items has acceptable measurement properties and can inform day-to-day variations in symptomatic AEs when daily PRO-CTCAE administration is implemented in a clinical trial.
Collapse
Affiliation(s)
- M K Lee
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
| | - E Basch
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | | | | | - B T Langlais
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA
| | | | - B F Ginos
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA
| | - L J Rogak
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - A V Bennett
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA
| | - D Schrag
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - G L Mazza
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA
| | - A C Dueck
- Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ, USA
| |
Collapse
|
2
|
Mendoza TR, Dueck AC, Shi Q, Ma H, Zhang J, Qian Y, Cleeland CS. The contribution of pain in determining the health status of cancer patients with bone metastases: A secondary analysis of data from three Phase III registration trials. Eur J Pain 2017; 22:565-571. [DOI: 10.1002/ejp.1139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/05/2017] [Indexed: 11/12/2022]
Affiliation(s)
- T. R. Mendoza
- Department of Symptom Research; The University of Texas MD Anderson Cancer Center; Houston TX USA
| | - A. C. Dueck
- Department of Biostatistics; Mayo Clinic in Arizona; Scottsdale AZ USA
| | - Q. Shi
- Department of Symptom Research; The University of Texas MD Anderson Cancer Center; Houston TX USA
| | - H. Ma
- Amgen; Thousand Oaks CA USA
| | | | | | - C. S. Cleeland
- Department of Symptom Research; The University of Texas MD Anderson Cancer Center; Houston TX USA
| |
Collapse
|
3
|
Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ. Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial. Blood Cancer J 2016; 6:e396. [PMID: 26871714 PMCID: PMC4771967 DOI: 10.1038/bcj.2016.4] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2015] [Accepted: 01/04/2016] [Indexed: 01/01/2023] Open
Abstract
The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive therapy. A majority of patients (81.8%) completed the minimal number or more of the four required cycles, while two patients completed only three cycles. The maximum tolerated dose (MTD) of siltuximab with RVD was dose level −1 (siltuximab: 8.3 mg/kg; bortezomib: 1.3 mg/m2; lenalidomide: 25 mg; dexamethasone: 20 mg). Serious adverse events were grade 3 pneumonia and grade 4 thrombocytopenia, and no deaths occurred during the study or with follow-up (median follow-up 28.1 months). An overall response rate, after 3–4 cycles of therapy, of 90.9% (95% confidence interval (CI): 58.7%, 99.8%) (9.1% complete response (95% CI: 0.2%, 41.3%), 45.5% very good partial response (95% CI: 16.7%, 76.6%) and 36.4% partial response (95% CI: 10.9%, 69.2%)) was seen. Two patients withdrew consent, and nine patients (81.8%) opted for autologous stem cell transplantation.
Collapse
Affiliation(s)
- J J Shah
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - L Feng
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - S K Thomas
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Z Berkova
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - D M Weber
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M Wang
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M H Qazilbash
- Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R E Champlin
- Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - T R Mendoza
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - C Cleeland
- Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - R Z Orlowski
- Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.,Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| |
Collapse
|
4
|
Torres MG, Mendoza TR, Guerrero IJ, Yamamoto NJ. Evaluación de la resistencia a la erosión ácida de dos ionómeros de vidrio utilizados en la técnica restaurativa atraumática (TRA), modificados con un antibiótico. Rev Cient Odontol (Lima) 2015. [DOI: 10.21142/2523-2754-0302-2015-326-332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
5
|
Habets EJ, Taphoorn MJ, Nederend S, Klein M, Delgadillo D, Hoang-Xuan K, Bottomley A, Allgeier A, Seute T, Gijtenbeek AM, De Gans J, Enting RH, Tijssen CC, Van den Bent MJ, Reijneveld JC, Xu H, Halbert K, Bliss R, Trusheim J, Hunt MA, Bunevicius A, Tamasauskas S, Tamasauskas A, Deltuva V, Field KM, Guyatt N, Fleet M, Rosenthal MA, Drummond KJ, Field KM, Fleet M, Guyatt N, Drummond KJ, Rosenthal MA, Oliver H, Tobias M, Eva V, Matthias S, Johannes S, Oliver S, Christian TJ, Dietmar K, Gabriele S, Thomas R, Nikkhah G, Uwe S, Markus L, Michael W, Manfred W, Strowd RE, Swett K, Harmon M, Pop-Vicas A, Chan M, Tatter SB, Ellis TL, Blevins M, High K, Lesser GJ, Benouaich-Amiel A, Taillandier L, Vercueil L, Valton L, Szurhaj W, Idbaih A, Delattre JY, Loiseau H, Klein I, Block V, Ramirez C, Laigle-Donadey F, Le Rhun E, Harrison C, Van Horn A, Sapienza C, Schlimper C, Schlag H, Weber F, Acquaye AA, Gilbert MR, Armstrong TS, Acquaye AA, Vera-Bolanos E, Gilbert MR, Armstrong TS, Walbert T, Armstrong TS, Elizabeth VB, Gilbert M, Affronti ML, Woodring S, Allen K, Herndon JE, McSherry F, Peters KB, Friedman HS, Desjardins A, Freeman W, Cheshire S, Cone C, Kalinowski KH, Kim JY, Lay HH, Poillucci V, Southerland C, Tetterton J, Kirkpatrick J, Vredenburgh JJ, Affronti ML, Woodring S, Herndon JE, McSherry F, Peters KB, Friedman HS, Desjardins A, Freeman W, Cheshire S, Cone C, Kalinowski KH, Kim JY, Lay HH, Poillucci V, Southerland C, Tetterton J, Vredenburgh JJ, Edelstein K, Coate L, Mason WP, Jewitt NC, Massey C, Devins GM, Lin L, Chiang HH, Acquaye AA, Vera-Bolanos E, Cahill JE, Gilbert MR, Armstrong TS, Amidei CM, Lovely M, Page MD, Mogensen K, Arzbaecher J, Lupica K, Maher ME, Lin L, Acquaye AA, Vera-Bolanos E, Cahill JE, Gilbert MR, Armstrong TS, Duong HT, Kelly DF, Peters KB, Woodring S, Herndon JE, McSherry F, Vredenburgh JJ, Desjardins A, Friedman HS, Gning I, Armstrong TS, Wefel JS, Acquaye AA, Vera-Bolanos E, Mendoza TR, Gilbert MR, Cleeland CS, Guthikonda B, Thakur JD, Banerjee A, Shorter C, Sonig A, Khan IS, Gardner GL, Nanda A, Reddy K, Gaspar L, Kavanagh B, Waziri A, Chen C, Boele F, Hoeben W, Hilverda K, Lenting J, Calis AL, Sizoo E, Collette E, Heimans J, Postma T, Taphoorn M, Reijneveld J, Klein M. CLIN-SYMPTOM MANAGEMENT/QUALITY OF LIFE. Neuro Oncol 2012; 14:vi153-vi159. [PMCID: PMC3488794 DOI: 10.1093/neuonc/nos240] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2023] Open
|
6
|
Lucas MR, Robinson KM, Koh ES, Hovey EJ, Wright KM, Simpson T, Price MA, Shafiq J, Kaadan N, Barton MB, Armstrong T, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta M, Gilbert MR, Spezeski J, de Melo SM, Taylor LP, Otero H, Zuurveld MA, Peerdeman SM, Bouma GJ, Feller RE, Klein M, Aaronson NK, Taphoorn MJB, Heimans JJ, Postma TJ, Gundy CM, Beute GN, Slotman BJ, Klein M, Satoer D, Vincent A, Dirven C, Smits M, Visch-Brink E, Vera-Bolanos E, Armstrong TS, Mendoza T, Fisher A, Kuo CW, Sherwood P, Peters KB, Coan AD, West MJ, Reardon DA, Desjardins A, Vredenburgh JJ, Friedman HS, Jones LW, Acquaye AA, Lin L, Aspenson AS, Cahill J, Vera-Bolanos E, Gilbert MR, Armstrong TS, Lamki T, Ammirati M, Lin L, Acquaye AA, Vera-Bolanos E, Cahill J, Gilbert MR, Armstrong TS, Lin L, Acquaye AA, Vera-Bolanos E, Cahill J, Gilbert MR, Armstrong TS, Lai JS, Acquaye A, Armstrong TS, Acquaye AA, Lin L, Aspenson AC, Cahill J, Vera-Bolanos E, Gilbert MR, Armstrong TS, Stell BV, Jacobs DI, Grimm SA, Rademaker A, Rice L, Schwartz M, Chandler J, Muro K, Helenowki IB, Marymont MH, Wagner LI, Mehta M, Raizer J, Gerard ME, Drappatz J, Muzikansky A, Weiss S, Kesari S, Wong E, Fadul CE, Norden AD, Quant EC, Beroukhim R, Alexander B, Ruland S, Ciampa AS, LaFrankie DC, Sceppa C, Smith KH, Hammond SN, Wen PY, Farace E, Sheehan J, Bonneau R, Glantz M, McDonald KL, Ryu S, Rock J, Jain R, Casas C, Schultz L, Pace M, Aho T, Horio M, Doshi P, Cahill J, Padhye N, Vera-Bolanos E, Gning I, Mendoza T, Gilbert M, Armstrong T, Hoover JM, Mandrekar J, Meyer FB, Parney IF. QUALITY OF LIFE. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Gonzalez JDSR, Eduardo O, Salvador A, de la Mora Alejandra P, Peiffer AM, Leyrer CM, Greene-Schloesser D, Kearns WT, Hinson WH, Tatter SB, Rapp SR, Robbins ME, Shaw EG, Chan MD, de Groot M, Douw L, Sizoo EM, Bosma I, Froklage FE, Heimans JJ, Postma T, Reijneveld JC, Klein M, Froklage FE, Sizoo EM, de Groot M, Postma TJ, Taphoorn MJ, Bosma I, Oosterbaan L, Reijneveld JC, Heimans JJ, Douw L, Klein M, Wefel JS, Armstrong TS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman DG, Choucair AK, Mehta MP, Gilbert MR, Otten M, Mikell CB, Youngerman BE, Small SA, McKhann G, Slavc I, Leiss U, Dressler A, Peyrl A, Dieckmann K, Czech T, Correa DD, Baser R, Beal K, Sasan K, Lisa D, Panageas K, Barradas R, Statucka M, Abrey L, Gutin P, Omuro A, Robben R, Uitdehaag BMJ, Fagel SSAA, Taphoorn MJB, Postma TJ, Heimans JJ, Klein M, Gehring K, Sawyer AM, Etzel CJ, Lang FF, Wefel JS, Gehring K, Sawyer AM, Etzel CJ, Lang FF, Wefel JS. NEURO-COGNITIVE. Neuro Oncol 2011. [DOI: 10.1093/neuonc/nor166] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Walker R, Ruderman I, Masterson R, Cohney S, Salvadori M, Conti P, Bertoni E, Durrbach A, Citterio F, Mulloy L, David-Neto E, Russ G, Vitko S, Zhang R, Xing J, Harler MB, Grinyo J, Rugiu C, Trubian A, Bernich P, Lupo A, Asbe-Vollkopf A, Pannu A, Hoefeld H, Gauer S, Gossmann J, Kachel HG, Froese S, Korom S, Geiger H, Hauser IA, Liefeldt L, Kluener C, Glander P, Giessing M, Gralla O, Neumayer HH, Budde K, Kroencke T, Liborio AB, Barros RM, Esmeraldo RM, Oliveira MLMB, Nogueira Paes FJV, Mendoza TR, Silva Junior GB, Daher EF, Siekierka-Harreis M, Bantis C, Kouri NM, Schwandt C, Rump LC, Ivens K, Slatinska J, Honsova E, Burgelova M, Slimackova E, Viklicky O, Tabernero G, Rivero K, Fernandez G, Canueto J, Garcia P, Fraile P, Lucas C, Tabernero JM, Bargnoux AS, Simon N, Garrigue V, Dupuy AM, Mourad G, Cristol JP, Yapici U, Kers J, Bemelman F, Roelofs J, Groothoff J, van der Loos C, van Donselaar-van der Pant K, Idu M, Claessen N, ten Berge I, Florquin S, Knap B, Dragonja Z, Dobnik S, Buturovic Ponikvar J, Ponikvar R, Kandus A, Bren A, Hauser IA, Kleemann J, Gauer S, Engel J, Winter S, Hoefeld H, Asbe-Vollkopf A, Brzoska M, Obermueller N, Geiger H, Schaeffeler E, Oldak M, Pazik J, Lewandowski Z, Sitarek E, Dabrowski M, Ploski R, Malejczyk J, Durlik M, Slubowska K, Urbanowicz A, Sadowska A, Lichodziejewska B, Kurnicka K, Galazka Z, Chmura A, Durlik M, Masin-Spasovska J, Spasovski G, Petrusevska G, Popov Z, Ivanovski N, Di Napoli A, Salvatori MF, Franco F, Di Lallo D, Guasticchi G, Sancho A, Gavela E, Beltran S, Kanter J, Alemany B, Crespo JF, Pallardo LM, Lionet A, Beuscart JB, Buob D, BenHenda A, Provot F, Hazzan M, Noel C, Galan-Sanchez F, Marin-Casanova P, Mazuecos A, Garcia-Alvarez T, Aznar E, Rodriguez-Iglesias M, Ossareh S, Salami M, Mohammad E, Hosseini M, Pawlik A, Chudek J, Kolonko A, Wilk J, Jalowiecki P, Wiecek A, Zyablitskaya E, Galkina E, Yushina E, Botelho C, Aires P, Santos L, Romaozinho C, Macario F, Alves R, Veiga P, Mota A, Yashi M, Yagisawa T, Kimura T, Nukui A, Fujiwara T, Sakuma Y, Ishikawa N, Iwabuchi T, Muraishi O, Glander P, Hambach P, Liefeldt L, Neumayer HH, Budde K, Esmen S, Keven K, Sengul S, Ozcan M, Ensari A, Tuzuner A, Calayoglu R, Nergizoglu G, Gullu Koca T, Koca N, Ersoy A, Faria B, Bustorff M, Barros F, Tavares I, Santos J, Ferreira I, Sampaio S, Pestana M, Keven K, Suvak B, Sengul S, Kurultak I, Calayoglu R, Tutkak H, Choi HM, Yang HN, Jo SK, Cho WY, Kim HK, Aybal Kutlugun A, Altun B, Akman U, Aki T, Turkmen E, Yildirim T, Altindal M, Yilmaz R, Yasavul U, Gullu Koca T, Koca N, Ersoy A, Thiem U, Heinze G, Gossler U, Perkmann T, Kainberger F, Muhlbacher F, Horl W, Borchhardt K, Sanchez-Escuredo A, Holgado S, Biosca C, Granada ML, Barluenga E, Lauzurica R, Romero R, Espinal A, Torregrossa V, Bayes B, Tomida K, Hamano T, Fujii N, Ichimaru N, Matsui I, Isaka Y, Rakugi H, Takahara S, Gavela E, Sancho A, Kanter J, Beltran S, Avila A, Crespo JF, Pallardo LM, Dor F, Massey E, Frunza M, Johnson R, Lennerling A, Loven C, Mamode N, Pascalev A, Sterckx S, Van Assche K, Zuidema W, Weimar W, Botelho C, Aires P, Santos L, Romaozinho C, Macario F, Alves R, Veiga P, Mota A, Allwin R, Gauer S, Roessel, Hoefeld H, Brzoska M, Buettner S, Gossmann J, Belwe V, Geiger H, Hauser IA, Apaza J, Gonzalez E, Polanco N, Bengoa I, Cadenillas C, Andres A, Morales JM, Rocha S, Fonseca I, Martins LS, Vidinha J, Dias L, Almeida M, Pedroso S, Henriques A, Cabrita A, Neretljak I, Mihovilovic K, Vidas Z, Jurenec F, Knotek M, Justa S, Minz R, Minz M, Anand S, Sharma A, Lacquaniti A, Donato V, Chirico V, Pettinato G, Buemi M, Galle J, Addison J, Perry P, Claes K, Farouk M, Guerin A, Kiss I, Winearls C, Di Giulio S, Basic-Jukic N, Slavicek J, Bubic-Filipi L, Kes P, Scholbach T, Wang HK, Yang AH, Loong CC, Wu TH, Abboud I, Antoine C, Serrato T, Lefaucheur C, Pillebout E, Gaudez F, Fieux F, Flamant M, Verine J, Viglietti D, Peraldi MN, Glotz D. Transplantation: clinical studies (2). Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Crespo M, Collado S, Mir M, Hurtado S, Cao H, Barbosa F, Serra C, Hidalgo C, Faura A, Garcia de Lomas J, Montero M, Horcajada JP, Puig JM, Pascual J, Ulusal Okyay G, Uludag K, Sozen H, Arman D, Dalgic A, Guz G, Fraile P, Garcia-Cosmes P, Rosado C, Gonzalez C, Tabernero JM, Costa C, Saldan A, Astegiano S, Terlizzi ME, Messina M, Bergallo M, Segoloni G, Cavallo R, Schwarz A, Grosshennig A, Heim A, Broecker V, Haller H, Linnenweber S, Liborio AB, Mendoza TR, Esmeraldo RM, Oliveira MLMB, Nogueira Paes FJV, Silva Junior GB, Daher EF, Hodgson K, Baharani J, Fenton A, Baharani J, Mjoen G, Hartmann A, Reisaeter A, Midtvedt K, Dahle DO, Holdaas H, Shabir S, Lukacik P, Bevins A, Basnayake K, Bental A, Hughes RG, Cockwell P, Burrows R, Hutchison CA, Varma P, Kumar A, Hooda A, Badwal S, Barrios C, Mir M, Crespo M, Fumado L, Frances A, Puig JM, Horcajada JP, Arango O, Pascual J, Pawlik A, Chudek J, Kolonko A, Wilk J, Jalowiecki P, Wiecek A, Teplan V, Kralova-Lesna I, Mahrova A, Racek J, tollova M, Maggisano V, Caracciolo V, Solazzo A, Montanari M, Della Grotta F, Nakazawa D, Nishio S, Nakagaki T, Ishikawa Y, Ito M, Shibazaki S, Shimoda N, Miura M, Morita K, Nonomura K, Koike T, Locsey L, Seres I, Sztanek F, Harangi M, Padra J, Asztalos L, Paragh G, Rodriguez-Reimundes E, Soler-Pujol G, Diaz CH, Davalos-Michel M, Vilches AR, Laham G, Mjoen G, Stavem K, Midtvedt K, Norby G, Holdaas H, Tutal E, Canver B, Can S, Sezer S, Colak T, Kolonko A, Chudek J, Wiecek A, Paschoalin R, Barros X, Duran C, Torregrosa JV, Crespo M, Mir M, Barrios C, Faura A, Tellez E, Marin M, Puig JM, Pascual J, Smalcelj R, Smalcelj A, Claes K, Petit T, Bammens B, Kuypers D, Naesens M, Vanrenterghem Y, Evenepoel P, Gerhart MK, Colbus S, Seiler S, Grun O, Fliser D, Heine GH, Vincenti F, Grinyo J, Larsen C, Medina Pestana J, Vanrenterghem Y, Dong Y, Thomas D, Charpentier B, Luna E, Martinez R, Cerezo I, Ferreira F, Cubero J, Villa J, Martinez C, Garcia C, Rodrigo E, Santos L, Pinera C, Quintela E, Ruiz JC, Fernandez-Fresnedo G, Palomar R, Gomez-Alamillo C, Martin de Francisco AL, Arias M, Grinyo J, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Dong Y, Thomas D, Kamar N, Durrbach A, Grinyo J, Vanrenterghem Y, Becker T, Florman S, Lang P, del Carmen Rial M, Schnitzler M, Duan T, Block A, Medina Pestana J, Sawosz M, Cieciura T, Durlik M, Perkowska A, Sikora P, Beck B, De Mauri A, Brambilla M, Stratta P, Chiarinotti D, De Leo M, Attou S, Arzour H, Boudrifa N, Mekhlouf N, Gaouar A, Merazga S, Kalem K, Haddoum F. Transplantation: clinical studies. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.43] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
10
|
Rosenthal DI, Gunn GB, Mendoza TR, Garden AS, Beadle BM, Morrison WH, Wang XS, Frank SJ, Weber RS, Ang KK, Cleeland CS. Long-term symptom burden after radiation treatment for oropharynx cancer: A comparison of 3D and IMRT techniques. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Orlowski RZ, Wang XS, Mendoza TR, Williams LA, Johnson VE, Joy J, Ilagan V, Mobley GM, Liu P, Gilmore KR, Cleeland CS. Prevalence and trajectory of disease- and treatment-related symptom burden in patients with multiple myeloma undergoing induction therapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19627] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Williams LA, Garcia-Gonzalez A, Ault P, Mendoza TR, Cleeland CS, Mobley GM, Williams JL, Cortes JE. A new symptom measure in chronic myeloid leukemia. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e19545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Armstrong TS, Wefel JS, Wang M, Won M, Bottomley A, Mendoza TR, Coens C, Werner-Wasik M, Brachman D, Choucair AK, Gilbert MR. Clinical utility of neurocognitive function (NCF), quality of life (QOL), and symptom assessment as prognostic factors for survival and measures of treatment effects on RTOG 0525. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2016] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Mendoza TR, Gunn GB, Fuller CD, Wang XS, Rosenthal DI, Cleeland CS. The utility of using area under the curve to analyze symptom burden during radiation/chemoradiation for head and neck cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Gunn GB, Mendoza TR, Garden AS, Wang XS, Morrison WH, Frank SJ, Hanna EY, Lu C, Beadle BM, Ang KK, Cleeland CS, Rosenthal DI. Patient-reported fatigue in head and neck cancer survivors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5523] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Fisch M, Lee J, Weiss M, Wagner LI, Chang VT, Cella D, Manola J, Minasian LM, McCaskill-Stevens WJ, Mendoza TR, Cleeland CS. Prospective and observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Lucas MR, Armstrong TS, Acquaye A, Balachandran D, Mahajan A, Kang DH, Vera-Bolanos E, Gilbert MR, Lovely MP, Page M, Mogensen K, Arzbaecher J, Amidei C, Lupica K, Maher ME, Sherwood P, Kagan S, Sizoo EM, Pasman HRW, Reijneveld JC, Heimans JJ, Deliens L, Taphoorn MJ, Sheth R, Bagan BT, Baig MN, Karas C, Jacobs DI, Grimm SA, Rademaker A, Rice L, Chandler JP, Muro K, Marymount M, Helenowski IB, Wagner LI, Bennett CL, Raizer JJ, Evans A, Dhall G, Finlay J, Wong K, McComb G, Soffietti R, Mueller RP, Abacioglu U, Villa S, Fauchon F, Baumert B, Fariselli L, Tridello G, Kocher M, Bottomley A, Pendleton C, Adams H, Jallo GI, Carson BS, Ahn E, Quinones-Hinojosa A, Acquaye AA, Vera-Bolanos E, Armstrong TS, Bekele BN, Gilbert MR, Jacobs DI, Grimm SA, Rademaker A, Rice L, Chandler J, Muro K, Marymount M, Helenowski IB, Wagner LI, Raizer JJ, Nestor V, Fink K, Nashed M, Linskey M, Bota DA, Hoeben W, Hilverda K, Heimans JJ, Taphoorn MJ, Postma TJ, Buter J, Lenting J, Collette EH, Reijneveld JC, Klein M, van Nieuwenhuizen D, Bosscher L, Szymanska E, Heimans JJ, Peerdeman SM, Klein M, Reijneveld JC, van Nieuwenhuizen D, Erdmann T, Heimans JJ, Reijneveld JC, Peerdeman SM, Klein M, Lawrence Recht SN, Armstrong T, Vera-Bolanos E, Gning I, Acquaye A, Gilbert MR, Cleeland C, Mendoza TR, Jouniaux-Delbez N, Delattre JY, du Montcel ST, Butowski N, Parvataneni R, Nicole A, Lamborn K, Polley M, Clarke J, Chang S, Page M, Prados M, Liepa A, Shi P, Thornton D, Kahlenberg CA, Fadul CE, Scott R, Roberts DW, Thadani V, Bujarski K, Lallana EC, Jobst BC, Walker JG, Schultz D, Grisdale K, Groves MD, Peters KB, Reardon DA, Vredenburgh JJ, Desjardins A, Friedman HS, Allen DH, Carlson B, Neelon V, Giovanello K, Carlson J, Raynor R, Desjardins A, Rice L, Lall R, Ha S, Marymont M, Grimm S, Raizer J, Chandler J, Muro K, Keir ST. Quality of Life. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Dueck AC, Mendoza TR, Reeve BB, Sloan JA, Cleeland CS, Hay J, Li Y, O'Mara AM, Denicoff A, Basch EM. Validation study of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.tps274] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Mendoza TR, Koyyalagunta L, Burton AW, Thomas SK, Giralt S, Shah JJ, Ting J, Perez-Toro MR, Cleeland CS. The impact of pain reduction on other symptoms in patients with multiple myeloma-related painful vertebral fracture treated with kyphoplasty or vertebroplasty. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Atkinson TM, Sit L, Mendoza TR, Fruscione M, Lavene D, Shaw M, Breitbart W, Rosenfeld B, Cleeland CS, Basch EM. Confirmatory factor analysis to evaluate construct validity of the Brief Pain Inventory (BPI). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19505] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Wang XS, Fogelman DR, Eng C, Malekifar M, Reynolds RJ, Shah NA, Mendoza TR, Glover KY, Dougherty PM, Cleeland CS. Prospective study of paresthetic neurotoxicity from oxaliplatin-based regimens in the treatment of colorectal cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.3585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
22
|
Basch EM, Reeve BB, Cleeland CS, Sloan JA, Mendoza TR, Abernethy AP, Bruner D, Minasian LM, Burke LB, Schrag D. Development of the patient-reported version of the common terminology criteria for adverse events (PRO-CTCAE). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Hay J, Atkinson TM, Mendoza TR, Reeve BB, Willis G, Gagne JJ, Abernethy AP, Cleeland CS, Schrag D, Basch EM. Refinement of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) via cognitive interviewing. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Rosenthal DI, Mendoza TR, Gunn GB, Wang XS, Hessel AC, Garden AS, Morrison WH, Cleeland CS. The persistence of symptom burden after radiation treatment for head and neck cancer (HNC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5573] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Palos GR, Mendoza TR, Liao KE, Garcia-Gonzalez A, Hahn K, Nazario LA, Lynch GR, Anderson KO, Wang XS, Cleeland CS. Predictors of high symptom severity in caregivers of underserved minority cancer patients. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Cleeland CS, Mendoza TR, Palos GR, Lu C, Nazario LA, Lynch GR, Mobley GM, Wang XS. Factors contributing to high symptom burden during chemotherapy for advanced lung cancer: The risk of being underserved. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.9003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Gunn GB, Mendoza TR, Wang XS, Garden AS, Lewin JS, Morrison WH, Frank SJ, Chambers MS, Cleeland CS, Rosenthal DI. The relationship of presenting symptom burden and survival in patients with head and neck cancer (HNC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5600] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Anderson KO, Giralt SA, Mendoza TR, Brown JO, Neumann JL, Mobley GM, Wang XS, Cleeland CS. Symptom burden in patients undergoing autologous stem-cell transplantation. Bone Marrow Transplant 2007; 39:759-66. [PMID: 17438588 DOI: 10.1038/sj.bmt.1705664] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Patients who undergo autologous peripheral blood stem cell (PBSC) transplantation experience multiple symptoms that adversely affect quality of life. We assessed symptoms during the acute phase of autologous PBSC transplantation to determine the severity of individual symptoms and to determine overall symptom profiles in 100 patients with multiple myeloma or non-Hodgkin's lymphoma. Study subjects completed the blood and marrow transplantation module of the M. D. Anderson Symptom Inventory before hospitalization, during conditioning, on day of transplantation, at nadir (the time of lowest white blood cell count) and on day 30 post-transplantation. Additional symptom, quality-of-life and medical status measures were collected. Symptom means were mild at baseline, intensified during conditioning, peaked at nadir and decreased by day 30. At nadir, the most severe symptoms for the entire patient sample were lack of appetite, fatigue, weakness, feeling sick, disturbed sleep, nausea and diarrhea. Cancer diagnosis was a significant predictor of changes in symptoms over time. The patterns of fatigue, pain, sleep disturbance and lack of appetite were significantly different for patients with multiple myeloma as compared with patients with non-Hodgkin's lymphoma.
Collapse
Affiliation(s)
- K O Anderson
- Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Cleeland CS, Portenoy RK, Rue M, Mendoza TR, Weller E, Payne R, Kirshner J, Atkins JN, Johnson PA, Marcus A. Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group. Ann Oncol 2005; 16:972-80. [PMID: 15821119 DOI: 10.1093/annonc/mdi191] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices. PATIENTS AND METHODS A pain management protocol was developed based on accepted guidelines. After baseline assessment, oncology practices were randomly assigned to 'analgesic protocol' (AP) sites, where oncologists implemented the guidelines in a group of lung or prostate cancer patients, or to 'physician discretion' (PD) sites, where customary treatment was continued. Patients treated on protocol and a comparison group of patients with pain due to breast cancer or myeloma were monitored for change in pain using the Brief Pain Inventory, and for change in other symptoms or mood. RESULTS The protocol terminated early because of poor accrual. We compared groups using proportions of patients who had no or mild pain at follow-up. Although measures of protocol adherence did not suggest the occurrence of major practice change, the proportion of lung or prostate cancer patients with no or mild pain increased significantly from baseline for those treated at AP sites compared with those treated at PD sites. There was no significant difference between the breast and myeloma patients treated at AP sites versus those treated at PD sites. CONCLUSION A protocol for cancer pain management can improve pain control. Diffusion of these benefits to other patients was not confirmed. Given the small sample size, these findings require confirmation in a larger trial.
Collapse
Affiliation(s)
- C S Cleeland
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Rosenthal DI, Chambers MS, Mendoza TR, Asper JA, Kies MS, Weber RS, Garden AS, Ang KK, Wang XS, Cleeland CS. The reliability and validity of the M. D. Anderson Symptom Inventory (MDASI-HN) as a measure of symptom burden in the head and neck cancer (HNC) patient population. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8097] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | - K. K. Ang
- M.D. Anderson Cancer Ctr, Houston, TX
| | | | | |
Collapse
|
31
|
Wang XS, Giralt S, Warneke CL, Mendoza TR, Albitar M, Brown JO, Anderson KO, Cleeland CS. Longitudinal assessment of IL-6 and symptom severity in multiple myeloma patients during first 30 days of autologous BMT. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- X. S. Wang
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - S. Giralt
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - C. L. Warneke
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - T. R. Mendoza
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - M. Albitar
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - J. O. Brown
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - K. O. Anderson
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| | - C. S. Cleeland
- University of Texas M. D. Anderson Cancer Center, Houston, TX; Nichols Institute, San Juan Capistrano, CA
| |
Collapse
|
32
|
Abstract
BACKGROUND The aim of this study was to evaluate the severity and patterns of fatigue during preoperative chemoradiation therapy for locally advanced rectal cancer and determine whether there are predictors for patients who develop severe fatigue. METHODS Seventy-two patients with resectable rectal cancer received chemoradiation (total radiation dose, 45 gray/25 fractions to the pelvis; continuous infusion of 5-fluorouracil [300 mg/m(2)]). The Brief Fatigue Inventory (BFI), a measure that categorizes fatigue severity on a 0-10 scale, was administered weekly during treatment. Severe fatigue was defined as 7-10 on the "worst level of fatigue" item. Demographics, disease information, toxicities, and blood counts were collected. Descriptive statistics, repeated measure analysis of variance, and multiple regression were used to examine fatigue and its correlates. RESULTS Fatigue increased in 67% of patients during chemoradiation (CTX/XRT). The mean fatigue score increased from 3.16 before treatment to 4.62 at the end of treatment. A significant linear trend suggested that fatigue progressively got worse during CTX/XRT (F = 16.497, P < 0.001). However, 18% of patients experienced severe fatigue before CTX/XRT; this was predicted by uncontrolled pain (r(2) = 0.321; F = 16.52; P < 0.001). During CTX/XRT, uncontrolled diarrhea was the only predictor for increased fatigue (r(2) = 0.182; F = 7.77; P < 0.01). Approximately one-third of patients had severe fatigue, which impaired their function at the end of CTX/XRT. CONCLUSIONS Preoperative chemoradiation therapy for patients with rectal cancer was associated with progressive fatigue during therapy. Based on identified predictors for fatigue, more active pain management before CXT/XRT and bowel management during CTX/XRT might reduce cancer-related fatigue in these patients.
Collapse
Affiliation(s)
- X S Wang
- Pain Research Group,The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
| | | | | | | | | | | | | | | |
Collapse
|
33
|
Abstract
Cancer-related fatigue is now the most prevalent symptom of cancer, occurring in 60-90% of patients. Fatigue has been identified by cancer patients as a factor influencing functionality and quality of life. Our objectives in developing a fatigue specialty clinic at The University of Texas M. D. Anderson Cancer Center were to improve our patients' quality of life by decreasing fatigue; educate health care providers, patients, and patients' families about cancer-related fatigue; develop an appropriate clinical and diagnostic evaluation for this symptom; correlate objective measures of fatigue with its clinical evaluation; and develop innovative treatment plans for cancer-related fatigue. This article describes the general clinic design and operations and the preliminary analysis of the first 40 patients evaluated in the fatigue clinic.
Collapse
Affiliation(s)
- C P Escalante
- Department of General Internal Medicine, Ambulatory Treatment and Emergency Care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Abstract
The increasing number of palliative care patients necessitates a simple, reliable instrument to routinely measure outcomes among hospice patients. We tested the utility of the Brief Hospice Inventory (BHI) to assess outcomes of hospice patients and estimations of patients' outcomes by nurse caregivers. In a prospective study, 145 home-based hospice patients were enrolled in the study from VistaCare Hospice. During the first week of admission, patients and nurse caregivers completed the BHI, which assessed patients' symptoms, satisfaction with care, and quality of life. Factor analysis supported a two-factor structure for the BHI for patients and caregivers, including a symptom subscale and quality of life subscale. Patients with severe symptoms showed improvement on the symptom subscale, but not the quality of life subscale, during the first 2 weeks after admission. The BHI shows utility in measuring hospice patients' symptom severity and quality of life over time.
Collapse
Affiliation(s)
- H Guo
- Pain Research Group, The University of Texas M. D. Anderson Cancer Center, 1100 Holcombe Blvd. Houston, TX 77030, USA
| | | | | | | |
Collapse
|
35
|
Abstract
BACKGROUND The purpose of this project was to develop the M. D. Anderson Symptom Inventory (MDASI), a brief measure of the severity and impact of cancer-related symptoms. METHODS A list of symptoms was generated from symptom inventories and by panels of clinicians. Twenty-six symptoms and 6 interference items were rated by a validation sample of 527 outpatients, a sample of 30 inpatients from the blood and bone marrow transplantation service, and a cross-validation sample of 113 outpatients. Clinical judgment and statistical techniques were used to reduce the number of symptoms. Reliability, validity, and sensitivity of the MDASI were examined. RESULTS Cluster analysis, best subset analysis, and clinical judgment reduced the number of symptoms to a "core" list of 13 that accounted for 64% of the variance in symptom distress. Factor analysis demonstrated a similar pattern in both outpatient samples, and two symptom factors and the interference scale were reliable. Expected differences in symptom pattern and severity were found between patients with "good" versus "poor" performance status and between patients in active therapy and patients who were seen for follow-up. Patients rated fatigue-related symptoms as the most severe. Groups of patients classified by disease or treatment had severe symptoms that were not on the "core" list. CONCLUSIONS The core items of the MDASI accounted for the majority of symptom distress reported by cancer patients in active treatment and those who were followed after treatment. The MDASI should prove useful for symptom surveys, clinical trials, and patient monitoring, and its format should allow Internet or telephone administration.
Collapse
Affiliation(s)
- C S Cleeland
- Pain Research Group, Division of Anesthesiology and Critical Care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
36
|
Abstract
BACKGROUND The purpose of this project was to develop the M. D. Anderson Symptom Inventory (MDASI), a brief measure of the severity and impact of cancer-related symptoms. METHODS A list of symptoms was generated from symptom inventories and by panels of clinicians. Twenty-six symptoms and 6 interference items were rated by a validation sample of 527 outpatients, a sample of 30 inpatients from the blood and bone marrow transplantation service, and a cross-validation sample of 113 outpatients. Clinical judgment and statistical techniques were used to reduce the number of symptoms. Reliability, validity, and sensitivity of the MDASI were examined. RESULTS Cluster analysis, best subset analysis, and clinical judgment reduced the number of symptoms to a "core" list of 13 that accounted for 64% of the variance in symptom distress. Factor analysis demonstrated a similar pattern in both outpatient samples, and two symptom factors and the interference scale were reliable. Expected differences in symptom pattern and severity were found between patients with "good" versus "poor" performance status and between patients in active therapy and patients who were seen for follow-up. Patients rated fatigue-related symptoms as the most severe. Groups of patients classified by disease or treatment had severe symptoms that were not on the "core" list. CONCLUSIONS The core items of the MDASI accounted for the majority of symptom distress reported by cancer patients in active treatment and those who were followed after treatment. The MDASI should prove useful for symptom surveys, clinical trials, and patient monitoring, and its format should allow Internet or telephone administration.
Collapse
Affiliation(s)
- C S Cleeland
- Pain Research Group, Division of Anesthesiology and Critical Care, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
| | | | | | | | | | | | | |
Collapse
|
37
|
Anderson KO, Mendoza TR, Valero V, Richman SP, Russell C, Hurley J, DeLeon C, Washington P, Palos G, Payne R, Cleeland CS. Minority cancer patients and their providers: pain management attitudes and practice. Cancer 2000; 88:1929-38. [PMID: 10760771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
BACKGROUND The goals of the current studies were: 1) to determine the pain treatment needs of socioeconomically disadvantaged African-American and Hispanic patients with recurrent or metastatic cancer and 2) to assess the attitudes of health care professionals who treat them. METHODS In the first study 108 African-American and Hispanic patients with metastatic or recurrent cancer and pain completed a survey about their pain intensity, pain interference, and attitudes toward analgesic medications. Physicians also rated their patients' pain and the adequacy of the patients' current analgesic prescriptions was assessed. In the second study 55 physicians and nurses who treat these patients completed a questionnaire regarding cancer pain and its management in their practice settings. RESULTS Approximately 28% of the Hispanic and 31% of the African-American patients received analgesics of insufficient strength to manage their pain. Although the majority of patients received appropriate analgesics, 65% reported severe pain. Physicians underestimated pain severity for 64% of the Hispanic and 74% of the African-American patients. Physicians were more likely to underestimate the pain severity of female patients than male patients. Inadequate pain assessment, patient reluctance to report pain, and lack of staff time were perceived as barriers to pain management. CONCLUSIONS Although the data suggest recent improvements in analgesic prescribing practices for African-American and Hispanic cancer patients, the majority of patients reported high levels of pain and limited pain relief from analgesic medications. Inadequate pain assessment remains a major barrier to optimal cancer pain treatment.
Collapse
Affiliation(s)
- K O Anderson
- Pain Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Wang XS, Cleeland CS, Mendoza TR, Engstrom MC, Liu S, Xu G, Hao X, Wang Y, Ren XS. The effects of pain severity on health-related quality of life: a study of Chinese cancer patients. Cancer 1999; 86:1848-55. [PMID: 10547560] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
BACKGROUND The health-related functioning of patients with cancer is compromised by several factors, including the disease process, treatment, and the various symptoms that are produced by both disease and treatment. This study was designed to specify the relationship between patients' pain severity and their self-reported quality of life. METHODS The study enrolled 216 consecutive consenting adult patients from 2 Chinese cancer centers with pathologically-diagnosed metastatic cancer who could understand and complete the self-report measures. The majority had cancer-related pain and were receiving analgesics. The Chinese version of the Brief Pain Inventory was used to assess the severity and interference of pain. A Chinese translation of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) was used to assess health-related functional status. Patients' physicians completed a form that indicated characteristics of the patients' cancer, Eastern Cooperative Oncology Group performance status, pain, and current pain treatment. RESULTS Increasing severity of pain was associated with worsening health-related functioning, even when an estimate of disease severity was taken into account. The correlation between pain severity and impairment was nonlinear. The functional health and well-being of cancer patients with no or mild pain was significantly less impaired than that of patients with moderate or severe pain. The impairment of patients with moderate and severe pain did not differ. CONCLUSIONS Pain severity is an important variable to be taken into account when quality of life outcome measures are considered. The functioning of cancer patients with well-controlled (mild) pain did not differ significantly from that of patients without pain. Providing pain relief should significantly improve the functional status of cancer patients.
Collapse
Affiliation(s)
- X S Wang
- Pain Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Abstract
BACKGROUND Fatigue is a major disease and treatment burden for cancer patients. Several scales have been created to measure fatigue, but many are long and difficult for very ill patients to complete, or they are not easy to translate for non-English speaking patients. The Brief Fatigue Inventory was developed for the rapid assessment of fatigue severity for use in both clinical screening and clinical trials. METHODS The study enrolled 305 consecutive, consenting adult inpatients and outpatients with cancer who could understand and complete the self-report measures used in the study. The same instruments also were administered to 290 community-dwelling adults to obtain a comparison sample. Research staff completed a form that indicated the primary site and stage of the cancer, rated the Eastern Cooperative Oncology Group performance status of the patient, described the characteristics of the pain, and described the current pain treatment being provided to the patients. RESULTS The BFI was shown to be an internally stable (reliable) measure that tapped a single dimension, best interpreted as severity of fatigue. It correlated highly with similar fatigue measures. Greater than 98% of patients were able to complete it. A range of scores defining severe fatigue was identified. CONCLUSIONS The BFI is a reliable instrument that allows for the rapid assessment of fatigue level in cancer patients and identifies those patients with severe fatigue.
Collapse
Affiliation(s)
- T R Mendoza
- Pain Research Group, The University of Texas M. D. Anderson Cancer Center, Houston, USA
| | | | | | | | | | | | | |
Collapse
|
40
|
Abstract
We describe the development of a Chinese version of the Brief Pain Inventory (BPI-C) and demonstrate its reliability and validity. We also report the use of the BPI-C in a three hospital study of cancer pain and its treatment. As with other language versions of the BPI, factor analysis of the BPI-C items results in a two factor solution that satisfies the criteria of reproducibility, interpretability and fit in a confirmatory setting. The first factor consists of the four pain severity scales, while the seven pain interference scales comprised the second factor. The BPI-C proved to be a reliable measure of both the severity and impact of pain in patients with cancer. Coefficient alpha for the pain severity and pain interference items were 0.894 and 0.915, respectively. The sample (N = 147) was gathered at three cancer treatment hospitals in Beijing. The patients from these hospitals reported higher levels of pain severity and pain interference compared with patients in similar studies done at the time (1991-1992) in the United States and France. This was in keeping with the finding that a larger proportion (67%) of the cancer patients in these Beijing hospitals were judged to have inadequate analgesia as assessed by the Pain Management Index (PMI), an estimate of adherence to the World Health Organization (WHO) guidelines for cancer pain management.
Collapse
Affiliation(s)
- X S Wang
- Department of Neurology, University of Wisconsin, Madison 53705, USA
| | | | | | | |
Collapse
|
41
|
Cleeland CS, Nakamura Y, Mendoza TR, Edwards KR, Douglas J, Serlin RC. Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain 1996; 67:267-73. [PMID: 8951920 DOI: 10.1016/0304-3959(96)03131-4] [Citation(s) in RCA: 177] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We investigated the question of how cultural and linguistic backgrounds affect relationships among ratings (reported by patients with metastatic cancer) of pain's interference with such functions as activity, mood, and sleep. Multidimensional scaling (MDS) was used to analyze ratings of pain interference from a sample consisting of four culturally and linguistically different groups from the US (n = 1106), France (n = 324), the Philippines (n = 267), and China (n = 146). Patients all completed the Brief Pain Inventory, a self-report measure of pain and its interference with function. For each of these samples, MDS solutions consistently revealed two interpretable dimensions. In all samples, one dimension represented affect and the other dimension represented activity. The dimensions were consistently interpretable across all four samples and across three levels of pain severity ('mild', 'moderate', and 'severe'). The dimensions were most prominent when pain was moderate, rather than mild (when little interference was produced) or severe (when all domains were highly interfered with). These dimensions may have utility in the study of the epidemiology of pain and of the effectiveness of pain treatment. They may also be useful in clinical assessment to describe different patterns of pain interference.
Collapse
Affiliation(s)
- C S Cleeland
- Department of Neurology, University of Wisconsin, Madison, USA
| | | | | | | | | | | |
Collapse
|